Plato Investment Management Ltd Sells 1,414 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Plato Investment Management Ltd decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHRFree Report) by 35.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,594 shares of the biotechnology company’s stock after selling 1,414 shares during the quarter. Plato Investment Management Ltd’s holdings in United Therapeutics were worth $929,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. ClariVest Asset Management LLC lifted its stake in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in shares of United Therapeutics during the second quarter worth $30,000. Innealta Capital LLC bought a new position in shares of United Therapeutics in the 2nd quarter valued at $33,000. USA Financial Formulas bought a new stake in United Therapeutics during the 3rd quarter worth $33,000. Finally, Capital Performance Advisors LLP acquired a new position in United Therapeutics in the 3rd quarter worth about $82,000. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other United Therapeutics news, Director Nilda Mesa sold 224 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $412.28, for a total value of $92,350.72. Following the transaction, the director now owns 5,783 shares in the company, valued at approximately $2,384,215.24. This represents a 3.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Judy D. Olian sold 1,750 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the transaction, the director now directly owns 5,655 shares in the company, valued at $2,332,574.40. The trade was a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 113,396 shares of company stock worth $42,175,418. 11.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on UTHR shares. Wells Fargo & Company lifted their price target on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Bank of America decreased their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Argus boosted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $370.86.

View Our Latest Report on UTHR

United Therapeutics Price Performance

NASDAQ UTHR opened at $386.27 on Friday. The stock has a market capitalization of $17.25 billion, a P/E ratio of 16.96, a P/E/G ratio of 1.17 and a beta of 0.56. The business has a 50 day simple moving average of $362.57 and a 200 day simple moving average of $326.65. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHRGet Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the prior year, the business earned $5.38 EPS. Equities analysts expect that United Therapeutics Co. will post 25.1 earnings per share for the current year.

United Therapeutics Profile

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.